What are the effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding?

BEEM Bottom Line

Why is this study important?

Tranexamic acid (TXA) has been studied to control bleeding in trauma, postpartum hemorrhage and surgery. Small randomized controlled trials (RCT) have examined TXA as an adjunctive therapy in gastrointestinal bleeding (GIB). This HALT-IT RCT aimed to definitively determine the safety and efficacy of TXA for GIB with mortality as the primary outcome.

Which, if any, threats to validity are most likely to have an impact on the results and how?

Thank you for your interest in the BEEM Journal!

To read the rest of this article or to access the entire collection of BEEM Critical Appraisals, please purchase a subscription at the link below.

If you would like a pre-view, click here to view some sample articles

Premium Content Available Through Subscription

BEEM is a knowledge translation project which aims to extract the most recent, EM relevant, and valid evidence from the volumes of available medical research and deliver it to EM practitioners in an easily consumable format to help guide their clinical practice. This valuable distilled information provided by BEEM is available through BEEM's accredited CME courses or through our online journal.

A BEEM Journal Subscription will provide you with unlimited access to our entire collection of Critical Appraisals for 1 year.